Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.85 |
| ▸ | PSMB1 | P20618 | 6/20 | 0.76 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.76 |
| ▸ | PSMB2 | P49721 | 6/20 | 0.76 |
| ▸ | LTA4H | P09960 | 7/20 | 0.68 |
| ▸ | ESR1 | P03372 | 1/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL224627 | 1.00 | HRH3 (0.85) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL8973201 | 0.98 | HRH3 (0.82) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| Hydroxyamine SCHEMBL6816656 | 0.97 | HRH3 (0.80) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL4089206 | 0.92 | HRH3 (1.00) | HRH3 | |
| SCHEMBL6657187 | 0.87 | HRH3 (0.86) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL12128339 | 0.87 | HRH3 (0.85) | HRH3 | |
| SCHEMBL17826374 | 0.87 | PSMB1 (0.71) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL9056254 | 0.85 | HRH3 (0.83) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL30777699 | 0.85 | HRH3 (1.00) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL3580727 | 0.85 | HRH3 (1.00) | HRH3PSMB1PSMB5PSMB2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107793344-B | Industrial production method of bazedoxifene acetate | 扬子江药业集团有限公司 | 2021-01-12 | — | — | CN | claimed |
| CN-107793344-B | Industrial production method of bazedoxifene acetate | 扬子江药业集团有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-9751835-B2 | Processes and intermediates for preparing indole pharmaceuticals | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751835-B2 | Processes and intermediates for preparing indole pharmaceuticals | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160107991-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING INDOLE PHARMACEUTICALS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2016-04-21 | — | — | US | disclosed |
| US-20160107991-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING INDOLE PHARMACEUTICALS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2016-04-21 | — | — | US | disclosed |
| WO-2014186325-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING INDOLE PHARMACEUTICALS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2014-11-20 | — | — | WO | disclosed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| WO-2012079154-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | DALHOUSIE UNIVERSITY (CA) | 2012-06-21 | — | — | WO | disclosed |
| US-20080207898-A1 | PROCESSES FOR THE PREPARATION OF AMINOETHOXYBENZYL ALCOHOLS | WYETH (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207898-A1 | PROCESSES FOR THE PREPARATION OF AMINOETHOXYBENZYL ALCOHOLS | WYETH (US) | 2008-08-28 | — | — | US | disclosed |
| US-7375251-B2 | Processes for the preparation of aminoethoxybenzyl alcohols | WYETH (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375251-B2 | Processes for the preparation of aminoethoxybenzyl alcohols | WYETH (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375251-B2 | Processes for the preparation of aminoethoxybenzyl alcohols | WYETH (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1836155-A2 | PROCESSES FOR THE PREPARATION OF AMINOETHOXYBENZYL ALCOHOLS | Wyeth, A Corporation of the State of Delaware (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006076350-A2 | PROCESSES FOR THE PREPARATION OF AMINOETHOXYBENZYL ALCOHOLS | WYETH (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060155147-A1 | Processes for the preparation of aminoethoxybenzyl alcohols | WYETH (US) | 2006-07-13 | — | — | US | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207898-A1 | PROCESSES FOR THE PREPARATION OF AMINOETHOXYBENZYL ALCOHOLS | ADH1A, ADH1C, ADH5 | HRH3 1480/4885PSMB1 2032/4885PSMB5 1992/4885 |
| US-20060155147-A1 | Processes for the preparation of aminoethoxybenzyl alcohols | ADH1A, ADH1C, ADH5 | HRH3 1480/4885PSMB1 2032/4885PSMB5 1992/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | HRH3 114/4885PSMB1 1323/4885PSMB5 1564/4885 |
| US-20160107991-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING INDOLE PHARMACEUTICALS | CYP19A1, IDO1, IDO2 | HRH3 1724/4885PSMB1 2543/4885PSMB5 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.